Project Details
| Acronym | ACT16849 |
|---|---|
| Status | Active |
| Effective start/end date | 13/05/21 → 15/04/26 |
A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants with lung cancer or pleural mesothelioma
- Park, John (Primary Chief Investigator)
- Chapman, Nicola (Clinical Trial Unit Staff)
- Tan, Pearlyn (Clinical Trial Unit Staff)
Project: Research